Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Diovan Panel Finalizes Report following Fine-Tuning
April 14, 2014
- “Transparency Must Be Ensured” for Funding by Pharmas: Minister
April 14, 2014
- Number of High-Cost New Drugs to Be Reimbursed Under Fee-for-Service System: Chuikyo
April 14, 2014
- Japan NIH Will Have Research Topic-Based Units to Stem Sectionalism: Official
April 11, 2014
- Japanese NIH-Related Bills Clear Lower House
April 11, 2014
- 14-Day Prescription Limit to Be Ruled Out for Anti-HIV Drug Tivicay
April 11, 2014
- Official Says Health Ministry Will Notify Industry about Electronic Data Submissions around June
April 11, 2014
- Abe’s Govt, Pharma Leaders to Hold Public-Private Dialogue on April 14
April 10, 2014
- MHLW Says Additional Data Needed for OBLEAN Listing
April 10, 2014
- Chuikyo OKs Listing of 14 APIs including Japan’s First SGLT-2 Inhibitor
April 10, 2014
- PAFSC’s Committee Requires Face-to-Face Consultations for Sale of 25 OTC Drugs Including Allegra FX
April 10, 2014
- MHLW’s Study Committee on Clinical Research Systems to Hold 1st Meeting on April 17
April 10, 2014
- PMDA Announces Ongoing Evaluation of Benambax for Risk of Severe Bradycardia
April 9, 2014
- FPMAJ Not Giving Up on Perpetuation of Premium for New Drug Development: Committee Chair
April 9, 2014
- MHLW, MEXT, and METI Map Out New 10-Year Strategy for Cancer Research
April 8, 2014
- Ministry Panel Starts Reviewing Five-Year Promotion Plan for Clinical Research
April 8, 2014
- Japan NIH to Kick in with 300 Workers, 200 of Them on Contract
April 7, 2014
- Novartis’ Cover-Up Attempt over SIGN Trial “Outrageous”: Minister
April 7, 2014
- PMDA Opens New Office to Prepare for Introduction of CDISC Standards
April 4, 2014
- MHLW Sets New Target Review Periods for Diagnostics to Speed up Regulatory Processes
April 2, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…